Preliminary Trial of the Effect of Glucocorticoid Receptor Antagonist on Borderline Personality Disorder (BPD)
Study Details
Study Description
Brief Summary
Participants will be randomized to either Mifepristone 600mg once daily for seven days or Placebo tablet once daily for seven days. Rating scales, vital signs, cortisol levels will be collected for evaluation.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 2 |
Detailed Description
Mifepristone is an antagonist of type II glucocorticoid (GR-II) receptors, which has shown safety, efficacy, and good tolerability in the treatment of psychotic major depression (PMD). Like BPD, Hypothalamic-pituitary-adrenal (HPA) axis hyper-responsiveness appears to play a role in PMD pathophysiology. Belanoff et al. (2002) hypothesized that mifepristone causes a normalizing "resetting" of HPA axis rhythm, accounting for its efficacy in PMD. Mifepristone produces a marked (2- to 3- fold) compensatory increase in central cortisol levels via its antagonism of GR-II receptors. This consequent central cortisol elevation may then be able to counteract abnormally heightened corticotrophin-releasing hormone (CRH) activity via enhanced negative feedback mechanisms.
This is a proof of principle study of mifepristone in the treatment of individuals with BPD and histories of childhood abuse, which aims to translate neurobiological research concerning HPA axis abnormalities in BPD into a novel clinical intervention for patients. This project will also explore an innovative approach to the structure of pharmacotherapy for BPD. Specifically, we will employ the circumscribed (finite) drug administration period used in prior studies of mifepristone in neuropsychiatric illness, which differs from the current clinical practice of indefinite daily usage of medications. We hypothesize that mifepristone will beneficially impact stress response neurobiology and consequently ameliorate associated BPD symptoms.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Mifepristone Mifepristone 600mg once daily x 7 days |
Drug: mifepristone
Mifepristone 600mg (3x200mg tablets) once daily for seven days
|
| Placebo Comparator: Placebo Matching placebo tablets one daily |
Drug: Placebo
3 tablets once daily for seven days
|
Outcome Measures
Primary Outcome Measures
- Rapid Symptom Change [Baseline to 7 days of study medication]
To evaluate whether mifepristone will produce rapid symptom change after seven days of active treatment, as measured by Borderline Personality Disorder Severity Index (BPDSI) total score. The BPDSI is a semi-structured clinical interview assessing the frequency and severity of manifestations of Borderline Personality Disorder (BPD) during a circumscribed period of the previous 7 days. The BPDSI measures 9 symptoms associated with BPD on a Likert scale ranging from 0-7 (0 = never; 7 = daily). Each symptom measure produces a mean score ranging from 0-7, with a higher score indicating more prevalent symptoms. A total score is then calculated using the summed symptom mean scores, ranging from 0-63, with a higher score indicating more prevalent symptoms.
- Durable Symptom Change [7 days of study medication to 21 days after discontinuation of study medication]
To evaluate whether seven days of mifepristone treatment will result in a durable change in symptoms persisting after active treatment discontinuation, as measured by Borderline Personality Disorder Severity Index (BPDSI) total score. The BPDSI is a semi-structured clinical interview assessing the frequency and severity of manifestations of Borderline Personality Disorder (BPD) during a circumscribed period of the previous 7 days. The BPDSI measures 9 symptoms associated with BPD on a Likert scale ranging from 0-7 (0 = never; 7 = daily). Each symptom measure produces a mean score ranging from 0-7, with a higher score indicating more prevalent symptoms. A total score is then calculated using the summed symptom mean scores, ranging from 0-63, with a higher score indicating more prevalent symptoms.
- Number of Participants With Possibly and Probably Related Adverse Events [Baseline to 21 days after discontinuation of study medication]
To determine the safety and tolerability of mifepristone according to subject report of possibly and probably related adverse events (AEs). AEs were evaluated by study physicians at each visit and each reported AE was evaluated for relatedness (unrelated, possibly related, or probably related) to the study drug/procedure.
- Levels of Cortisol [Baseline (Visit 2), 7 days of study medication (Visit 4), 7 days after discontinuation of study medication (Visit 5), 21 days after discontinuation of study medication (Visit 6)]
To assess cortisol levels as a potential biomarker of hypothalamic-pituitary-adrenal (HPA)-axis engagement
Secondary Outcome Measures
- Symptom Change - BPDSI Subscales [Baseline (Visit 2)]
Borderline Personality Disorder Severity Index (BPDSI) symptom domain subscales scores. The BPDSI is a semi-structured clinical interview assessing the frequency and severity of manifestations of Borderline Personality Disorder (BPD) during a circumscribed period of the previous 7 days. The BPDSI measures 9 symptoms associated with BPD on a Likert scale ranging from 0-7 (0 = never; 7 = daily). Each symptom measure produces a mean score ranging from 0-7, with a higher score indicating more prevalent symptoms.
- Symptom Change - BPRS [Baseline (Visit 2), 7 days of study medication (Visit 4), 7 days after discontinuation of study medication (Visit 5), 21 days after discontinuation of study medication (Visit 6)]
The Brief Psychiatric Rating Scale (BPRS) is an 19-item scale measuring positive symptoms, general psychopathology and affective symptoms during the last 7 days. The BPRS measures symptoms with scores ranging from 0-7, with a higher score indicating more severity. A total score is then calculated by adding all the item scores, ranging from 0-133, with a higher score indicating more severity.
- Symptom Change - Borderline Checklist [Baseline (Visit 2), 7 days of study medication (Visit 4), 7 days after discontinuation of study medication (Visit 5), 21 days after discontinuation of study medication (Visit 6)]
The Borderline Personality Checklist (BPD Checklist) is a 47-item DSM-IV based self-report questionnaire, designed to assess the experienced burden of specific BPD symptoms during the previous week. The BPD Checklist measures symptoms with scores ranging from 1-5, with a higher score indicating more severity. A total score is then calculated by adding all the item scores, ranging from 47-235, with a higher score indicating more severity.
- Symptom Change - SCL-90-R [Baseline (Visit 2)]
The Symptom Checklist-90-Revised (SCL-90-R) instrument helps evaluate a broad range of psychological problems and symptoms of psychopathology. The instrument is also useful in measuring patient progress or treatment outcomes. The SCL-90-R contains 90 items on a 5-point rating scale, with a higher score indicating more severity. The items are categorized into 12 domains (9 scores along primary symptom dimensions and 3 scores among global distress indices). A t-score for each domain is then obtained by norming by sex and ranges between 19-81, with a higher score indicating more severity.
- Metacognitive Capacity [Baseline, 21 days after discontinuation of study medication]
The Indiana Psychiatric Illness Interview (IPII) is a semi-structured interview developed to assess illness narratives. Responses are audio taped and later transcribed. It is scored using the Metacognition Assessment Scale- Abbreviated (MAS-A), which has four domains of metacognition: i) Self-Reflectivity ranging from 0-9; ii) Understanding the Mind of Other ranging from 0-7; iii) Decentration ranging from 0-3; and iv) Mastery ranging from 0-9. Lower scores indicate metacognitive deficits, higher scores indicate more integrated and nuanced metacognition. MAS-A total score is the sum of the scores on each of the domains of metacognition, ranging from 0-28, with a lower score indicating metacognitive deficits and a higher score indicating more integrated and nuanced metacognition.
- Symptom Change - CGI-S [Baseline, 7 days of study medication (Visit 4), 21 days after discontinuation of study medication (Visit 6)]
The Clinical Global Impressions Severity Scale (CGI-S) is used for repeated evaluations of global psychopathology. The CGI-S scale is widely used in schizophrenia research and is a single 7-point Likert scale rating severity of psychopathology on a scale of 1 (normal, not ill) to 7 (very severely ill), with a higher score indicating more severity.
- Symptom Change - CGI-I [7 days of study medication (Visit 4), 21 days after discontinuation of study medication (Visit 6)]
The Clinical Global Impressions Improvement (CGI-I) scale is used to assess the clinical change as compared to symptoms at baseline using a 7-point Likert scale, ranging from very much improved (1) to very much worse (7), with a higher score indicating more severity.
- Symptom Change - BPDSI Subscales [7 days of study medication (Visit 4)]
Borderline Personality Disorder Severity Index (BPDSI) symptom domain subscales scores. The BPDSI is a semi-structured clinical interview assessing the frequency and severity of manifestations of Borderline Personality Disorder (BPD) during a circumscribed period of the previous 7 days. The BPDSI measures 9 symptoms associated with BPD on a Likert scale ranging from 0-7 (0 = never; 7 = daily). Each symptom measure produces a mean score ranging from 0-7, with a higher score indicating more prevalent symptoms.
- Symptom Change - BPDSI Subscales [21 days after discontinuation of study medication (Visit 6)]
Borderline Personality Disorder Severity Index (BPDSI) symptom domain subscales scores. The BPDSI is a semi-structured clinical interview assessing the frequency and severity of manifestations of Borderline Personality Disorder (BPD) during a circumscribed period of the previous 7 days. The BPDSI measures 9 symptoms associated with BPD on a Likert scale ranging from 0-7 (0 = never; 7 = daily). Each symptom measure produces a mean score ranging from 0-7, with a higher score indicating more prevalent symptoms.
- Symptom Change - SCL-90-R [7 days of study medication (Visit 4)]
The Symptom Checklist-90-Revised (SCL-90-R) instrument helps evaluate a broad range of psychological problems and symptoms of psychopathology. The instrument is also useful in measuring patient progress or treatment outcomes. The SCL-90-R contains 90 items on a 5-point rating scale, with a higher score indicating more severity. The items are categorized into 12 domains (9 scores along primary symptom dimensions and 3 scores among global distress indices). A t-score for each domain is then obtained by norming by sex and ranges between 19-81, with a higher score indicating more severity.
- Symptom Change - SCL-90-R [21 days after discontinuation of study medication (Visit 6)]
The Symptom Checklist-90-Revised (SCL-90-R) instrument helps evaluate a broad range of psychological problems and symptoms of psychopathology. The instrument is also useful in measuring patient progress or treatment outcomes. The SCL-90-R contains 90 items on a 5-point rating scale, with a higher score indicating more severity. The items are categorized into 12 domains (9 scores along primary symptom dimensions and 3 scores among global distress indices). A t-score for each domain is then obtained by norming by sex and ranges between 19-81, with a higher score indicating more severity.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
18-64 years of age at study entry
-
Female or Male
-
Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR) diagnosis of borderline personality disorder (confirmed by SCID II) with history of abuse prior to the age of 18.
-
Able to provide informed consent
-
Inpatient or outpatient
-
Clinical stability as defined by:
-
Subjects must not have experienced an exacerbation of their illness within 4 weeks prior to randomization, leading to an intensification of psychiatric care in the opinion of the principal investigator. Examples of intensification of care include, but are not limited to: inpatient hospitalization, day/partial hospitalization, outpatient crisis management, or psychiatric treatment in an emergency room AND
-
Psychotropic treatment stability for at least 2 weeks prior to randomization (no change in dosing or addition of any new psychotropic medication)
-
Female subjects of childbearing potential must test negative for pregnancy at screening visit and agree to use the double-barrier method, as defined by 2 physical barriers such as a condom, diaphragm, or cervical occlusive cap, coupled with an additional barrier such as spermicidal foam, gel, film, cream or suppository for the duration of the study. Subjects having undergone a hysterectomy or bilateral oophorectomy or other form of female sterilization or patients having been medically confirmed to be post-menopausal, would not require any other method of contraception.
-
Minimum severity of a total score > 3 on the The Clinical Global Impression severity (CGI-S)
-
Must agree not to consume tonic water and grapefruit or grapefruit product for 3 days prior to beginning medication and until the final study visit
Exclusion Criteria:
-
DSM-IV TR diagnosis of (confirmed by SCID) schizophrenia or a related psychotic disorder, bipolar I disorder, or dementia
-
Subjects who are considered prisoners per the Indiana University Standard Operating Procedures for Research Involving Human Subjects.
-
Subjects with current acute, serious, or unstable medical conditions, including, but not limited to: inadequately controlled diabetes, asthma, Chronic obstructive pulmonary disease (COPD), severe hypertriglyceridemia, recent cerebrovascular accidents, acute systemic infection or immunologic disease, unstable cardiovascular disorders, malnutrition, renal gastroenterologic, respiratory, endocrinologic (particularly illnesses related to the HPA-axis, e.g., Cushing's Syndrome), neurologic, hematologic, or infectious diseases
-
Clinically significant electrocardiogram (ECG) abnormality prior to randomization including: subjects with a corrected QT interval (Bazett's; QTcB) >470 msec prior to randomization (based on the cardiologist overread). Repeat ECGs will be conducted at the discretion of the principal investigator or medical designee
-
Use of any exclusionary medications listed in the protocol Attachment 2: Concomitant Medications
-
Pregnant or lactating women or women who plan to become pregnant or will be lactating within one month after cessation of study medication
-
Known Intelligence quotient (IQ) <70 based on medical history
-
Currently using an intrauterine device (IUD) (females only)
-
History of treatment with mifepristone or any mifepristone-containing medication at any time
-
Known history of (1) Hepatitis C virus antibody, (2) Hepatitis B surface antigen (HBsAg) with or without positive Hepatitis B core total antibody, or (3) HIV 1 or 2 antibodies
-
Subjects with moderate to severe renal impairment as defined by creatinine clearance (CrCl) < 60 ml/min (measured by the Cockcroft-Gault equation) at screening
-
Subjects with hepatic impairment as defined by liver transaminases or total bilirubin
3 × upper limit of normal (ULN)
-
Subjects considered a high risk for suicidal acts, as determined by the principal investigator.
-
Subjects who have participated in a clinical trial with any pharmacological treatment intervention for which they received study-related medication in the 4 weeks prior to screening OR Subjects currently receiving treatment (within 1 dosing interval plus 4 weeks) with an investigational depot formulation of an antipsychotic medication
-
Subjects who demonstrate overtly aggressive behavior or who are deemed to pose a homicidal risk in the principal investigator's opinion
-
Psychosocial treatment changes 14 days prior to randomization
-
History of unexplained vaginal bleeding, endometrial hyperplasia with atypia, or endometrial carcinoma
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Larue D Carter Memorial Hospital | Indianapolis | Indiana | United States | 46222 |
Sponsors and Collaborators
- Indiana University
Investigators
None specified.Study Documents (Full-Text)
More Information
Additional Information:
Publications
None provided.- 1011002977
Study Results
Participant Flow
| Recruitment Details | |
|---|---|
| Pre-assignment Detail |
| Arm/Group Title | Mifepristone | Placebo |
|---|---|---|
| Arm/Group Description | Mifepristone 600mg once daily x 7 days mifepristone: Mifepristone 600mg (3x200mg tablets) once daily for seven days | Matching placebo tablets one daily Placebo: 3 tablets once daily for seven days |
| Period Title: Overall Study | ||
| STARTED | 10 | 12 |
| COMPLETED | 9 | 10 |
| NOT COMPLETED | 1 | 2 |
Baseline Characteristics
| Arm/Group Title | Mifepristone | Placebo | Total |
|---|---|---|---|
| Arm/Group Description | Mifepristone 600mg once daily x 7 days mifepristone: Mifepristone 600mg (3x200mg tablets) once daily for seven days | Matching placebo tablets one daily Placebo: 3 tablets once daily for seven days | Total of all reporting groups |
| Overall Participants | 10 | 12 | 22 |
| Age (Count of Participants) | |||
| <=18 years |
1
10%
|
0
0%
|
1
4.5%
|
| Between 18 and 65 years |
9
90%
|
12
100%
|
21
95.5%
|
| >=65 years |
0
0%
|
0
0%
|
0
0%
|
| Age (years) [Mean (Standard Deviation) ] | |||
| Mean (Standard Deviation) [years] |
40.90
(11.75)
|
33.42
(10.33)
|
36.82
(11.39)
|
| Sex: Female, Male (Count of Participants) | |||
| Female |
8
80%
|
11
91.7%
|
19
86.4%
|
| Male |
2
20%
|
1
8.3%
|
3
13.6%
|
| Ethnicity (NIH/OMB) (Count of Participants) | |||
| Hispanic or Latino |
0
0%
|
0
0%
|
0
0%
|
| Not Hispanic or Latino |
10
100%
|
12
100%
|
22
100%
|
| Unknown or Not Reported |
0
0%
|
0
0%
|
0
0%
|
| Race (NIH/OMB) (Count of Participants) | |||
| American Indian or Alaska Native |
0
0%
|
0
0%
|
0
0%
|
| Asian |
0
0%
|
0
0%
|
0
0%
|
| Native Hawaiian or Other Pacific Islander |
0
0%
|
0
0%
|
0
0%
|
| Black or African American |
2
20%
|
2
16.7%
|
4
18.2%
|
| White |
8
80%
|
9
75%
|
17
77.3%
|
| More than one race |
0
0%
|
0
0%
|
0
0%
|
| Unknown or Not Reported |
0
0%
|
1
8.3%
|
1
4.5%
|
| Region of Enrollment (participants) [Number] | |||
| United States |
10
100%
|
12
100%
|
22
100%
|
Outcome Measures
| Title | Rapid Symptom Change |
|---|---|
| Description | To evaluate whether mifepristone will produce rapid symptom change after seven days of active treatment, as measured by Borderline Personality Disorder Severity Index (BPDSI) total score. The BPDSI is a semi-structured clinical interview assessing the frequency and severity of manifestations of Borderline Personality Disorder (BPD) during a circumscribed period of the previous 7 days. The BPDSI measures 9 symptoms associated with BPD on a Likert scale ranging from 0-7 (0 = never; 7 = daily). Each symptom measure produces a mean score ranging from 0-7, with a higher score indicating more prevalent symptoms. A total score is then calculated using the summed symptom mean scores, ranging from 0-63, with a higher score indicating more prevalent symptoms. |
| Time Frame | Baseline to 7 days of study medication |
Outcome Measure Data
| Analysis Population Description |
|---|
| [Not Specified] |
| Arm/Group Title | Mifepristone | Placebo |
|---|---|---|
| Arm/Group Description | Mifepristone 600mg once daily x 7 days mifepristone: Mifepristone 600mg (3x200mg tablets) once daily for seven days | Matching placebo tablets one daily Placebo: 3 tablets once daily for seven days |
| Measure Participants | 10 | 12 |
| BPDSI Total Score after 7 days of medication |
13.5
(7.93)
|
9.45
(4.24)
|
| BPDSI Total Score at Baseline |
17.99
(6.65)
|
13.66
(7.72)
|
| Title | Durable Symptom Change |
|---|---|
| Description | To evaluate whether seven days of mifepristone treatment will result in a durable change in symptoms persisting after active treatment discontinuation, as measured by Borderline Personality Disorder Severity Index (BPDSI) total score. The BPDSI is a semi-structured clinical interview assessing the frequency and severity of manifestations of Borderline Personality Disorder (BPD) during a circumscribed period of the previous 7 days. The BPDSI measures 9 symptoms associated with BPD on a Likert scale ranging from 0-7 (0 = never; 7 = daily). Each symptom measure produces a mean score ranging from 0-7, with a higher score indicating more prevalent symptoms. A total score is then calculated using the summed symptom mean scores, ranging from 0-63, with a higher score indicating more prevalent symptoms. |
| Time Frame | 7 days of study medication to 21 days after discontinuation of study medication |
Outcome Measure Data
| Analysis Population Description |
|---|
| [Not Specified] |
| Arm/Group Title | Mifepristone | Placebo |
|---|---|---|
| Arm/Group Description | Mifepristone 600mg once daily x 7 days mifepristone: Mifepristone 600mg (3x200mg tablets) once daily for seven days | Matching placebo tablets one daily Placebo: 3 tablets once daily for seven days |
| Measure Participants | 10 | 12 |
| BPDSI Total Score after 7 days of medication |
13.50
(7.93)
|
9.45
(4.24)
|
| BPDSI Total Score 21 days after discont. study med |
13.58
(5.31)
|
8.17
(4.32)
|
| Title | Number of Participants With Possibly and Probably Related Adverse Events |
|---|---|
| Description | To determine the safety and tolerability of mifepristone according to subject report of possibly and probably related adverse events (AEs). AEs were evaluated by study physicians at each visit and each reported AE was evaluated for relatedness (unrelated, possibly related, or probably related) to the study drug/procedure. |
| Time Frame | Baseline to 21 days after discontinuation of study medication |
Outcome Measure Data
| Analysis Population Description |
|---|
| [Not Specified] |
| Arm/Group Title | Mifepristone | Placebo |
|---|---|---|
| Arm/Group Description | Mifepristone 600mg once daily x 7 days mifepristone: Mifepristone 600mg (3x200mg tablets) once daily for seven days | Matching placebo tablets one daily Placebo: 3 tablets once daily for seven days |
| Measure Participants | 10 | 12 |
| Number of subjects with possibly related AEs |
9
90%
|
6
50%
|
| Number of subjects with probably related AEs |
3
30%
|
3
25%
|
| Title | Levels of Cortisol |
|---|---|
| Description | To assess cortisol levels as a potential biomarker of hypothalamic-pituitary-adrenal (HPA)-axis engagement |
| Time Frame | Baseline (Visit 2), 7 days of study medication (Visit 4), 7 days after discontinuation of study medication (Visit 5), 21 days after discontinuation of study medication (Visit 6) |
Outcome Measure Data
| Analysis Population Description |
|---|
| [Not Specified] |
| Arm/Group Title | Mifepristone | Placebo |
|---|---|---|
| Arm/Group Description | Mifepristone 600mg once daily x 7 days mifepristone: Mifepristone 600mg (3x200mg tablets) once daily for seven days | Matching placebo tablets one daily Placebo: 3 tablets once daily for seven days |
| Measure Participants | 10 | 12 |
| Cortisol Level - Baseline |
13.88
(5.39)
|
14.38
(8.58)
|
| Cortisol Level - 7 days of study med |
35.01
(17.41)
|
16.33
(9.50)
|
| Cortisol Level - 7 days after disc of study med |
20.91
(5.53)
|
14.30
(6.88)
|
| Cortisol Level - 21 days after disc study med |
11.90
(4.95)
|
15.73
(12.00)
|
| Title | Symptom Change - BPDSI Subscales |
|---|---|
| Description | Borderline Personality Disorder Severity Index (BPDSI) symptom domain subscales scores. The BPDSI is a semi-structured clinical interview assessing the frequency and severity of manifestations of Borderline Personality Disorder (BPD) during a circumscribed period of the previous 7 days. The BPDSI measures 9 symptoms associated with BPD on a Likert scale ranging from 0-7 (0 = never; 7 = daily). Each symptom measure produces a mean score ranging from 0-7, with a higher score indicating more prevalent symptoms. |
| Time Frame | Baseline (Visit 2) |
Outcome Measure Data
| Analysis Population Description |
|---|
| [Not Specified] |
| Arm/Group Title | Mifepristone | Placebo |
|---|---|---|
| Arm/Group Description | Mifepristone 600mg once daily x 7 days mifepristone: Mifepristone 600mg (3x200mg tablets) once daily for seven days | Matching placebo tablets one daily Placebo: 3 tablets once daily for seven days |
| Measure Participants | 10 | 12 |
| BPDSI Subscale Score - Abandonment |
1.46
(0.96)
|
1.36
(1.55)
|
| BPDSI Subscale Score - Interpersonal Relationships |
1.34
(0.91)
|
0.70
(0.77)
|
| BPDSI Subscale Score - Identity |
2.76
(1.14)
|
1.49
(1.34)
|
| BPDSI Subscale Score - Impulsivity |
0.78
(0.62)
|
0.32
(0.37)
|
| BPDSI Subscale Score - Parasuicidal Behavior |
0.48
(0.62)
|
0.30
(0.46)
|
| BPDSI Subscale Score - Affective Instability |
4.40
(1.79)
|
4.48
(2.41)
|
| BPDSI Subscale Score - Emptiness |
3.96
(2.17)
|
2.35
(1.39)
|
| BPDSI Subscale Score - Outbursts of Anger |
1.45
(1.27)
|
1.53
(2.36)
|
| BPDSI Sub. Score-Dissociation & Paranoid Ideation |
1.45
(0.98)
|
1.14
(1.28)
|
| Title | Symptom Change - BPRS |
|---|---|
| Description | The Brief Psychiatric Rating Scale (BPRS) is an 19-item scale measuring positive symptoms, general psychopathology and affective symptoms during the last 7 days. The BPRS measures symptoms with scores ranging from 0-7, with a higher score indicating more severity. A total score is then calculated by adding all the item scores, ranging from 0-133, with a higher score indicating more severity. |
| Time Frame | Baseline (Visit 2), 7 days of study medication (Visit 4), 7 days after discontinuation of study medication (Visit 5), 21 days after discontinuation of study medication (Visit 6) |
Outcome Measure Data
| Analysis Population Description |
|---|
| [Not Specified] |
| Arm/Group Title | Mifepristone | Placebo |
|---|---|---|
| Arm/Group Description | Mifepristone 600mg once daily x 7 days mifepristone: Mifepristone 600mg (3x200mg tablets) once daily for seven days | Matching placebo tablets one daily Placebo: 3 tablets once daily for seven days |
| Measure Participants | 10 | 12 |
| BPRS - Baseline |
37.70
(5.85)
|
37.50
(7.09)
|
| BPRS - 7 days of study medication |
33.90
(6.15)
|
33.36
(7.30)
|
| BPRS - 7 days after disc of study med |
35.78
(6.57)
|
33.50
(7.66)
|
| BPRS - 21 days after disc study med |
35.22
(6.34)
|
30.50
(5.44)
|
| Title | Symptom Change - Borderline Checklist |
|---|---|
| Description | The Borderline Personality Checklist (BPD Checklist) is a 47-item DSM-IV based self-report questionnaire, designed to assess the experienced burden of specific BPD symptoms during the previous week. The BPD Checklist measures symptoms with scores ranging from 1-5, with a higher score indicating more severity. A total score is then calculated by adding all the item scores, ranging from 47-235, with a higher score indicating more severity. |
| Time Frame | Baseline (Visit 2), 7 days of study medication (Visit 4), 7 days after discontinuation of study medication (Visit 5), 21 days after discontinuation of study medication (Visit 6) |
Outcome Measure Data
| Analysis Population Description |
|---|
| [Not Specified] |
| Arm/Group Title | Mifepristone | Placebo |
|---|---|---|
| Arm/Group Description | Mifepristone 600mg once daily x 7 days mifepristone: Mifepristone 600mg (3x200mg tablets) once daily for seven days | Matching placebo tablets one daily Placebo: 3 tablets once daily for seven days |
| Measure Participants | 10 | 12 |
| BPD Checklist - Baseline |
103.60
(30.83)
|
96.92
(26.29)
|
| BPD Checklist - 7 days of study med |
98.10
(27.22)
|
88.36
(32.02)
|
| BPD Checklist - 7 days after disc of study med |
91.56
(26.74)
|
82.80
(37.94)
|
| BPD Checklist - 21 days after disc study med |
87.89
(24.31)
|
78.80
(28.01)
|
| Title | Symptom Change - SCL-90-R |
|---|---|
| Description | The Symptom Checklist-90-Revised (SCL-90-R) instrument helps evaluate a broad range of psychological problems and symptoms of psychopathology. The instrument is also useful in measuring patient progress or treatment outcomes. The SCL-90-R contains 90 items on a 5-point rating scale, with a higher score indicating more severity. The items are categorized into 12 domains (9 scores along primary symptom dimensions and 3 scores among global distress indices). A t-score for each domain is then obtained by norming by sex and ranges between 19-81, with a higher score indicating more severity. |
| Time Frame | Baseline (Visit 2) |
Outcome Measure Data
| Analysis Population Description |
|---|
| [Not Specified] |
| Arm/Group Title | Mifepristone | Placebo |
|---|---|---|
| Arm/Group Description | Mifepristone 600mg once daily x 7 days mifepristone: Mifepristone 600mg (3x200mg tablets) once daily for seven days | Matching placebo tablets one daily Placebo: 3 tablets once daily for seven days |
| Measure Participants | 10 | 12 |
| SCl-90-R - Somatization |
55.80
(6.18)
|
50.25
(9.96)
|
| SCL-90-R - Obsessive-Complusive |
56.20
(8.48)
|
51.50
(9.04)
|
| SCL-90-R - Interpersonal Sensitivity |
56.50
(12.19)
|
51.58
(7.55)
|
| SCL-90-R - Depression |
54.40
(8.91)
|
49.75
(9.20)
|
| SCL-90-R - Anxiety |
52.60
(9.09)
|
47.17
(7.72)
|
| SCL-90-R - Hostility |
53.70
(8.54)
|
53.00
(7.60)
|
| SCL-90-R - Phobic Anxiety |
50.00
(8.94)
|
54.58
(11.05)
|
| SCL-90-R - Paranoid Ideation |
56.40
(9.75)
|
48.45
(7.66)
|
| SCL-90-R - Psychoticism |
52.20
(9.37)
|
47.67
(8.55)
|
| SCL-90-R - Global Severity Index |
55.20
(9.16)
|
50.00
(8.42)
|
| SCL-90-R - Positive Symptom Total |
55.90
(10.72)
|
49.00
(7.95)
|
| SCL-90-R - Positive Symptom Distress Index |
54.50
(7.49)
|
52.25
(8.92)
|
| Title | Metacognitive Capacity |
|---|---|
| Description | The Indiana Psychiatric Illness Interview (IPII) is a semi-structured interview developed to assess illness narratives. Responses are audio taped and later transcribed. It is scored using the Metacognition Assessment Scale- Abbreviated (MAS-A), which has four domains of metacognition: i) Self-Reflectivity ranging from 0-9; ii) Understanding the Mind of Other ranging from 0-7; iii) Decentration ranging from 0-3; and iv) Mastery ranging from 0-9. Lower scores indicate metacognitive deficits, higher scores indicate more integrated and nuanced metacognition. MAS-A total score is the sum of the scores on each of the domains of metacognition, ranging from 0-28, with a lower score indicating metacognitive deficits and a higher score indicating more integrated and nuanced metacognition. |
| Time Frame | Baseline, 21 days after discontinuation of study medication |
Outcome Measure Data
| Analysis Population Description |
|---|
| The IPII assessment was added to the study midway through the study therefore, the first 10 subjects did not have this assessments. |
| Arm/Group Title | Mifepristone | Placebo |
|---|---|---|
| Arm/Group Description | Mifepristone 600mg once daily x 7 days mifepristone: Mifepristone 600mg (3x200mg tablets) once daily for seven days | Matching placebo tablets one daily Placebo: 3 tablets once daily for seven days |
| Measure Participants | 6 | 6 |
| IIPI - Self-Reflectivity - Baseline |
5.08
(1.63)
|
4.63
(1.70)
|
| IIPI-Self-Reflectivity-21 days after dis study med |
5.25
(1.89)
|
3.90
(0.42)
|
| IIPI - Understanding Others - Baseline |
3.25
(1.08)
|
2.88
(1.31)
|
| IIPI-Understanding Others-21 days after dis meds |
2.75
(0.50)
|
2.50
(1.00)
|
| IIPI - Decentration - Baseline |
0.50
(0.45)
|
0.38
(0.48)
|
| IIPI-Decentration-21 days after dis meds |
0.38
(0.75)
|
0.20
(0.45)
|
| IIPI - Mastery - Baseline |
2.67
(1.89)
|
3.88
(2.10)
|
| IIPI-Mastery-21 days after dis meds |
2.75
(0.50)
|
2.80
(1.64)
|
| IIPI - Total - Baseline |
11.50
(4.69)
|
11.75
(4.99)
|
| IIPI-Total-21 days after dis meds |
11.13
(2.95)
|
9.40
(2.43)
|
| Title | Symptom Change - CGI-S |
|---|---|
| Description | The Clinical Global Impressions Severity Scale (CGI-S) is used for repeated evaluations of global psychopathology. The CGI-S scale is widely used in schizophrenia research and is a single 7-point Likert scale rating severity of psychopathology on a scale of 1 (normal, not ill) to 7 (very severely ill), with a higher score indicating more severity. |
| Time Frame | Baseline, 7 days of study medication (Visit 4), 21 days after discontinuation of study medication (Visit 6) |
Outcome Measure Data
| Analysis Population Description |
|---|
| [Not Specified] |
| Arm/Group Title | Mifepristone | Placebo |
|---|---|---|
| Arm/Group Description | Mifepristone 600mg once daily x 7 days mifepristone: Mifepristone 600mg (3x200mg tablets) once daily for seven days | Matching placebo tablets one daily Placebo: 3 tablets once daily for seven days |
| Measure Participants | 10 | 12 |
| CGI-S - Baseline |
4.30
(0.67)
|
4.42
(0.90)
|
| CGI-S - 7 days of study med |
4.20
(1.03)
|
4.09
(1.04)
|
| CGI-S - 21 days after disc of study med |
3.89
(0.93)
|
3.70
(0.95)
|
| Title | Symptom Change - CGI-I |
|---|---|
| Description | The Clinical Global Impressions Improvement (CGI-I) scale is used to assess the clinical change as compared to symptoms at baseline using a 7-point Likert scale, ranging from very much improved (1) to very much worse (7), with a higher score indicating more severity. |
| Time Frame | 7 days of study medication (Visit 4), 21 days after discontinuation of study medication (Visit 6) |
Outcome Measure Data
| Analysis Population Description |
|---|
| The CGI-I is measured at visits after baseline, there was 1 subject taking Placebo who discontinued prior to Visit 4 and therefore was not included in analysis. |
| Arm/Group Title | Mifepristone | Placebo |
|---|---|---|
| Arm/Group Description | Mifepristone 600mg once daily x 7 days mifepristone: Mifepristone 600mg (3x200mg tablets) once daily for seven days | Matching placebo tablets one daily Placebo: 3 tablets once daily for seven days |
| Measure Participants | 10 | 11 |
| CGI-I - 7 days of study med |
3.30
(1.16)
|
3.36
(1.29)
|
| CGI-I - 21 days after disc of study med |
3.44
(1.01)
|
2.80
(1.14)
|
| Title | Symptom Change - BPDSI Subscales |
|---|---|
| Description | Borderline Personality Disorder Severity Index (BPDSI) symptom domain subscales scores. The BPDSI is a semi-structured clinical interview assessing the frequency and severity of manifestations of Borderline Personality Disorder (BPD) during a circumscribed period of the previous 7 days. The BPDSI measures 9 symptoms associated with BPD on a Likert scale ranging from 0-7 (0 = never; 7 = daily). Each symptom measure produces a mean score ranging from 0-7, with a higher score indicating more prevalent symptoms. |
| Time Frame | 7 days of study medication (Visit 4) |
Outcome Measure Data
| Analysis Population Description |
|---|
| [Not Specified] |
| Arm/Group Title | Mifepristone | Placebo |
|---|---|---|
| Arm/Group Description | Mifepristone 600mg once daily x 7 days mifepristone: Mifepristone 600mg (3x200mg tablets) once daily for seven days | Matching placebo tablets one daily Placebo: 3 tablets once daily for seven days |
| Measure Participants | 10 | 12 |
| BPDSI Subscale Score - Abandonment |
0.90
(0.59)
|
1.27
(1.15)
|
| BPDSI Subscale Score - Interpersonal Relationships |
0.80
(0.54)
|
0.58
(0.53)
|
| BPDSI Subscale Score - Identity |
1.64
(1.13)
|
1.34
(0.85)
|
| BPDSI Subscale Score - Impulsivity |
0.66
(0.64)
|
0.11
(0.17)
|
| BPDSI Subscale Score - Parasuicidal Behavior |
0.37
(0.52)
|
0.19
(0.37)
|
| BPDSI Subscale Score - Affective Instability |
3.67
(2.43)
|
2.89
(1.90)
|
| BPDSI Subscale Score - Emptiness |
2.76
(1.81)
|
1.51
(0.91)
|
| BPDSI Subscale Score - Outbursts of Anger |
1.08
(1.20)
|
0.79
(0.92)
|
| BPDSI Sub. Score-Dissociation & Paranoid Ideation |
1.63
(1.26)
|
0.77
(0.84)
|
| Title | Symptom Change - BPDSI Subscales |
|---|---|
| Description | Borderline Personality Disorder Severity Index (BPDSI) symptom domain subscales scores. The BPDSI is a semi-structured clinical interview assessing the frequency and severity of manifestations of Borderline Personality Disorder (BPD) during a circumscribed period of the previous 7 days. The BPDSI measures 9 symptoms associated with BPD on a Likert scale ranging from 0-7 (0 = never; 7 = daily). Each symptom measure produces a mean score ranging from 0-7, with a higher score indicating more prevalent symptoms. |
| Time Frame | 21 days after discontinuation of study medication (Visit 6) |
Outcome Measure Data
| Analysis Population Description |
|---|
| [Not Specified] |
| Arm/Group Title | Mifepristone | Placebo |
|---|---|---|
| Arm/Group Description | Mifepristone 600mg once daily x 7 days mifepristone: Mifepristone 600mg (3x200mg tablets) once daily for seven days | Matching placebo tablets one daily Placebo: 3 tablets once daily for seven days |
| Measure Participants | 10 | 12 |
| BPDSI Subscale Score - Abandonment |
1.06
(0.75)
|
0.63
(0.67)
|
| BPDSI Subscale Score - Interpersonal Relationships |
0.84
(0.86)
|
0.64
(0.88)
|
| BPDSI Subscale Score - Identity |
1.92
(1.12)
|
0.63
(0.76)
|
| BPDSI Subscale Score - Impulsivity |
0.53
(0.58)
|
0.11
(0.14)
|
| BPDSI Subscale Score - Parasuicidal Behavior |
0.43
(0.38)
|
0.25
(0.37)
|
| BPDSI Subscale Score - Affective Instability |
3.27
(2.10)
|
2.96
(1.60)
|
| BPDSI Subscale Score - Emptiness |
2.94
(1.86)
|
1.79
(1.67)
|
| BPDSI Subscale Score - Outbursts of Anger |
0.97
(1.22)
|
0.62
(1.07)
|
| BPDSI Sub. Score-Dissociation & Paranoid Ideation |
1.62
(1.03)
|
0.56
(0.58)
|
| Title | Symptom Change - SCL-90-R |
|---|---|
| Description | The Symptom Checklist-90-Revised (SCL-90-R) instrument helps evaluate a broad range of psychological problems and symptoms of psychopathology. The instrument is also useful in measuring patient progress or treatment outcomes. The SCL-90-R contains 90 items on a 5-point rating scale, with a higher score indicating more severity. The items are categorized into 12 domains (9 scores along primary symptom dimensions and 3 scores among global distress indices). A t-score for each domain is then obtained by norming by sex and ranges between 19-81, with a higher score indicating more severity. |
| Time Frame | 7 days of study medication (Visit 4) |
Outcome Measure Data
| Analysis Population Description |
|---|
| [Not Specified] |
| Arm/Group Title | Mifepristone | Placebo |
|---|---|---|
| Arm/Group Description | Mifepristone 600mg once daily x 7 days mifepristone: Mifepristone 600mg (3x200mg tablets) once daily for seven days | Matching placebo tablets one daily Placebo: 3 tablets once daily for seven days |
| Measure Participants | 10 | 12 |
| SCl-90-R - Somatization |
53.00
(10.92)
|
46.27
(9.18)
|
| SCL-90-R - Obsessive-Complusive |
54.30
(11.49)
|
47.91
(9.69)
|
| SCL-90-R - Interpersonal Sensitivity |
53.00
(10.07)
|
48.45
(10.05)
|
| SCL-90-R - Depression |
52.60
(9.32)
|
47.82
(10.05)
|
| SCL-90-R - Anxiety |
49.10
(10.08)
|
43.09
(9.39)
|
| SCL-90-R - Hostility |
52.80
(9.07)
|
52.00
(10.85)
|
| SCL-90-R - Phobic Anxiety |
49.60
(6.59)
|
49.55
(7.88)
|
| SCL-90-R - Paranoid Ideation |
53.80
(10.38)
|
47.91
(8.88)
|
| SCL-90-R - Psychoticism |
48.80
(8.16)
|
47.27
(10.67)
|
| SCL-90-R - Global Severity Index |
52.30
(9.89)
|
45.82
(9.29)
|
| SCL-90-R - Positive Symptom Total |
53.40
(11.89)
|
46.91
(9.69)
|
| SCL-90-R - Positive Symptom Distress Index |
54.20
(11.49)
|
51.91
(17.04)
|
| Title | Symptom Change - SCL-90-R |
|---|---|
| Description | The Symptom Checklist-90-Revised (SCL-90-R) instrument helps evaluate a broad range of psychological problems and symptoms of psychopathology. The instrument is also useful in measuring patient progress or treatment outcomes. The SCL-90-R contains 90 items on a 5-point rating scale, with a higher score indicating more severity. The items are categorized into 12 domains (9 scores along primary symptom dimensions and 3 scores among global distress indices). A t-score for each domain is then obtained by norming by sex and ranges between 19-81, with a higher score indicating more severity. |
| Time Frame | 21 days after discontinuation of study medication (Visit 6) |
Outcome Measure Data
| Analysis Population Description |
|---|
| [Not Specified] |
| Arm/Group Title | Mifepristone | Placebo |
|---|---|---|
| Arm/Group Description | Mifepristone 600mg once daily x 7 days mifepristone: Mifepristone 600mg (3x200mg tablets) once daily for seven days | Matching placebo tablets one daily Placebo: 3 tablets once daily for seven days |
| Measure Participants | 10 | 12 |
| SCl-90-R - Somatization |
49.78
(15.21)
|
47.60
(10.70)
|
| SCL-90-R - Obsessive-Complusive |
51.33
(9.80)
|
44.60
(12.69)
|
| SCL-90-R - Interpersonal Sensitivity |
48.89
(10.48)
|
45.30
(8.79)
|
| SCL-90-R - Depression |
49.00
(9.86)
|
44.00
(12.44)
|
| SCL-90-R - Anxiety |
48.44
(9.25)
|
42.70
(10.27)
|
| SCL-90-R - Hostility |
50.11
(12.50)
|
48.80
(6.84)
|
| SCL-90-R - Phobic Anxiety |
46.00
(6.96)
|
50.10
(8.75)
|
| SCL-90-R - Paranoid Ideation |
50.33
(10.48)
|
46.80
(12.56)
|
| SCL-90-R - Psychoticism |
45.44
(8.50)
|
45.70
(13.31)
|
| SCL-90-R - Global Severity Index |
49.00
(10.30)
|
45.10
(12.05)
|
| SCL-90-R - Positive Symptom Total |
49.56
(11.22)
|
44.80
(10.40)
|
| SCL-90-R - Positive Symptom Distress Index |
51.67
(13.19)
|
46.60
(12.47)
|
Adverse Events
| Time Frame | Screening through 21 days after study medication was discontinued | |||
|---|---|---|---|---|
| Adverse Event Reporting Description | ||||
| Arm/Group Title | Mifepristone | Placebo | ||
| Arm/Group Description | Mifepristone 600mg once daily x 7 days mifepristone: Mifepristone 600mg (3x200mg tablets) once daily for seven days | Matching placebo tablets one daily Placebo: 3 tablets once daily for seven days | ||
All Cause Mortality |
||||
| Mifepristone | Placebo | |||
| Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | |
| Total | 0/10 (0%) | 0/12 (0%) | ||
Serious Adverse Events |
||||
| Mifepristone | Placebo | |||
| Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | |
| Total | 0/10 (0%) | 1/12 (8.3%) | ||
| Renal and urinary disorders | ||||
| Foreign body in urethra | 0/10 (0%) | 0 | 1/12 (8.3%) | 1 |
Other (Not Including Serious) Adverse Events |
||||
| Mifepristone | Placebo | |||
| Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | |
| Total | 10/10 (100%) | 10/12 (83.3%) | ||
| Blood and lymphatic system disorders | ||||
| Hypokalemia | 2/10 (20%) | 2 | 1/12 (8.3%) | 1 |
| Cardiac disorders | ||||
| Abnormal electrocardiogram | 2/10 (20%) | 2 | 1/12 (8.3%) | 1 |
| Eye disorders | ||||
| Blurry Vision | 2/10 (20%) | 2 | 0/12 (0%) | 0 |
| Dry Eyes | 1/10 (10%) | 1 | 0/12 (0%) | 0 |
| Gastrointestinal disorders | ||||
| Abdominal bloating | 0/10 (0%) | 0 | 1/12 (8.3%) | 1 |
| Abdominal Pain | 1/10 (10%) | 2 | 2/12 (16.7%) | 4 |
| Constipation | 1/10 (10%) | 1 | 0/12 (0%) | 0 |
| Diarrhea | 1/10 (10%) | 1 | 2/12 (16.7%) | 2 |
| Gastroenteritis | 0/10 (0%) | 0 | 1/12 (8.3%) | 1 |
| Nausea | 5/10 (50%) | 6 | 2/12 (16.7%) | 2 |
| General disorders | ||||
| Chills | 0/10 (0%) | 0 | 1/12 (8.3%) | 1 |
| Decreased Appetite | 0/10 (0%) | 0 | 1/12 (8.3%) | 1 |
| Decreased Concentration | 0/10 (0%) | 0 | 1/12 (8.3%) | 2 |
| Dizziness | 1/10 (10%) | 1 | 0/12 (0%) | 0 |
| Exhaustion | 1/10 (10%) | 1 | 1/12 (8.3%) | 1 |
| Hand tremor | 1/10 (10%) | 1 | 1/12 (8.3%) | 1 |
| Headache/migraine | 3/10 (30%) | 3 | 4/12 (33.3%) | 4 |
| Increased appetite | 0/10 (0%) | 0 | 1/12 (8.3%) | 1 |
| influenza | 0/10 (0%) | 0 | 1/12 (8.3%) | 1 |
| insomnia | 1/10 (10%) | 1 | 0/12 (0%) | 0 |
| Irritability | 0/10 (0%) | 0 | 2/12 (16.7%) | 2 |
| mouth sores | 1/10 (10%) | 1 | 0/12 (0%) | 0 |
| Sinus congestion | 1/10 (10%) | 1 | 0/12 (0%) | 0 |
| Somnolence | 3/10 (30%) | 3 | 0/12 (0%) | 0 |
| Toothache | 0/10 (0%) | 0 | 1/12 (8.3%) | 1 |
| Infections and infestations | ||||
| Upper respiratory infection | 1/10 (10%) | 1 | 2/12 (16.7%) | 2 |
| Musculoskeletal and connective tissue disorders | ||||
| Arthritis | 0/10 (0%) | 0 | 1/12 (8.3%) | 1 |
| Costochondritis | 1/10 (10%) | 1 | 0/12 (0%) | 0 |
| Fibromyalgia | 1/10 (10%) | 1 | 0/12 (0%) | 0 |
| Heaviness in legs | 0/10 (0%) | 0 | 1/12 (8.3%) | 1 |
| Pain | 3/10 (30%) | 3 | 1/12 (8.3%) | 1 |
| Pre-existing restless leg syndrome | 1/10 (10%) | 1 | 0/12 (0%) | 0 |
| Shakiness | 0/10 (0%) | 0 | 1/12 (8.3%) | 1 |
| Psychiatric disorders | ||||
| Anxiety | 1/10 (10%) | 1 | 1/12 (8.3%) | 1 |
| Exacerbation of borderline personality disorder | 0/10 (0%) | 0 | 2/12 (16.7%) | 2 |
| Renal and urinary disorders | ||||
| Hemorrhoids | 1/10 (10%) | 1 | 0/12 (0%) | 0 |
| Urinary tract infection | 0/10 (0%) | 0 | 3/12 (25%) | 3 |
| Reproductive system and breast disorders | ||||
| Cramping | 0/10 (0%) | 0 | 2/12 (16.7%) | 2 |
| Dysmenorrhea | 1/10 (10%) | 1 | 0/12 (0%) | 0 |
| lactation | 0/10 (0%) | 0 | 1/12 (8.3%) | 1 |
| menstural bleeding | 1/10 (10%) | 1 | 1/12 (8.3%) | 2 |
| Respiratory, thoracic and mediastinal disorders | ||||
| Asthma | 0/10 (0%) | 0 | 1/12 (8.3%) | 2 |
| lump in throat | 1/10 (10%) | 1 | 0/12 (0%) | 0 |
| Pharyngitis | 0/10 (0%) | 0 | 1/12 (8.3%) | 1 |
| Skin and subcutaneous tissue disorders | ||||
| Atopic Dermatitis | 0/10 (0%) | 0 | 1/12 (8.3%) | 1 |
| Bug Bites | 1/10 (10%) | 1 | 0/12 (0%) | 0 |
| Dog Bite Infection | 1/10 (10%) | 1 | 0/12 (0%) | 0 |
| Ecchymosis | 0/10 (0%) | 0 | 1/12 (8.3%) | 1 |
| Pruritus | 2/10 (20%) | 2 | 0/12 (0%) | 0 |
| Rash | 3/10 (30%) | 3 | 0/12 (0%) | 0 |
| Rosacea | 1/10 (10%) | 1 | 0/12 (0%) | 0 |
| worsening acne | 0/10 (0%) | 0 | 1/12 (8.3%) | 1 |
Limitations/Caveats
More Information
Certain Agreements
Principal Investigators are NOT employed by the organization sponsoring the study.
There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
Results Point of Contact
| Name/Title | Dr. Alan Breier |
|---|---|
| Organization | IndianaU |
| Phone | 317-880-8495 |
| abreier@iupui.edu |
- 1011002977